LV10839B - Remedy for prophylactics and treatment of lipoid and cholesterol metabolism upset, method for prophylactics and treatment thereof - Google Patents
Remedy for prophylactics and treatment of lipoid and cholesterol metabolism upset, method for prophylactics and treatment thereof Download PDFInfo
- Publication number
- LV10839B LV10839B LVP-93-1238A LV931238A LV10839B LV 10839 B LV10839 B LV 10839B LV 931238 A LV931238 A LV 931238A LV 10839 B LV10839 B LV 10839B
- Authority
- LV
- Latvia
- Prior art keywords
- galacturonic acid
- treatment
- prophylactics
- hjih
- acid derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Description
LV 10839
JīeKapcTBeHHoe cpe,acTBO aira προφιυκκτΗκιι h Jie^emia HapymeHHH Jirnionimoro h xojiecTepHHOBoro o6MeHa BemecTB h cnoco6 προφΗϋΐ3κτΗΚΗ h jichchhii 3ΊΉΧ HapymeHHH
OnHcaHue Ū3o6peTeHHe ohochtch k Ha3HaqaeMOMy opajībHo JieKapcTBeHHOMy cpeacTBy λλβ Jienemui η προφΗ.ΐ3κτΗΚΒ HapyineHHH o6MeHa eemecTB, OCOČeHHO AJIB BJIHHHHfl Ha JIHnOHAHblH H XOJieCTepHHOBbIH θ6ΜβΗ BemeCTB, cneaoBaTejibHo, mnepjiHnmeMHH h aTepocKJiepo3a. C αββηηχ ΒρβΜβΗ b 3ana/mbix npoMbiiujieHHbK crpaHax HaO.iioaaioT 6biCTpuH ροετ HapymeHHH o6MeHa eemecTB, oco6eHHO HapynieHHH aaipoeoro o6Mena, ochobhoh πρηϊηηοη κοτορυχ λβλλθτοη yciuieHHoe nHTaroie npn OAHOBpeMeHHOH OrpaHHHeHHOH nOZUUDKHOCTH. ΠοΟΤβΠβΗΗΟ 06pa3VK)TCH noBbiineHHbie ypoBHH onpe^ejieHHbix αηπηαοβ b κροΒΗ, KOTopue juejiHHHBaiOT phck aTepocKJiepoTHMecKHx cep^eMHbK η περΗφεριίΗβοκΗχ 3a6ojieeaHHH cocyaoB. Πρκ 3tom aaipu nepeHocaTcn UHpKyjumHeft κροβιι b φορΜβ MejibHaifuiHx KanejieK (χηλομηκροημ), κοτορωβ CTa6HjiH3npoBaHbi προτβΗΗΟΒοή πλθηκοη ( α - HJiH β - rjio6yjiHH). 2 OSHJībHoe noTpe6jieHHe M»ca nacTO πρηβολητ κ nepeno3HpoBKe xojiecTepHHa, τβκ κβκ 3τοτ CTepoim y*e b nocTaTOHHOM KOJinnecTBe 6HOCHHTe3HpyeTca b πθηθηη HejioeeKa. IIpHpoaHbiH MexaHH3M peryjiHpoBaHH» xojiecTepHHa npn 6oraTOM acnpaMH πητεηηη HapyuiaeTca, h 3το πρΗΒΟΛΗΤ κ HenpepbiBHOMy noBbiiueHHio xojiecTepuHa iuia3Mbi κροβΗ. TpyAHopacTBopHMbiH xojiecTepHH pacnojiaraercfl, Mexny npomM, b cocynHCTbix cTeHKax aopTbi, b ρογοβοη oooiiOMKe rjia3a h b xpycTajiHKe rjia3a. EloBbiuieHHbie ypoBHH xojiecTepHna b κροβΗ no MeHbineH Mepe nacTHHHO HecyT OTBeTCBenHOCTb 3a o6pa3oeaHHe apTepnajibHbix cieiepo30B cocynoB. ΓHnepxojiecTepHHeMna npencTaBjineT rHnepjiHnimeMHK), ecerna conpoBO)KaaiomyK) HapyuieHHe o6MeHa BeinecTB, κοτοροε MoaceT 6biTb oneHb αρκο BbipaaceHO Hanp. npn caxapnoM juiaoeTe.
Pa3JiHHHbie, c tohkh 3peHHa naToreHe3a, HMeioume ποχοηαιε CHMIITOMbl KapTHHbl 6θΛβ3ΗβΗ ΓΗΠβρτρΗΠΪΙΗΗερΗηβΜΗΗ-ΓΗΠθρ.ΙΗΠΗηεΜΗΗ, Τ.β. noMyTHeHHe cbiBopoTKH κροβΗ Gjiaronapn ΧΝυίΟΜΗΚρΟΗΒΜ (ooraTbie HenTpajībHbiM χηροΜ KanejibKH c /maMeTpoM no 1 hm) h ninepxoJi6CTepHH6MHH, T.e. noBbiuieHue conepjKaHHH xojiecTepnHa b njia3Me κροβΗ no Bbiine 200 μγ oSbenHHHiOT non o6iuhmh ποηητηημη ΓΗΠβρΛΗΠΟΠρΟΤΘΗΗβΜΗΗ HJIH ΓΗΠθρΛΗΠΗΛβΜΗΗ (cp. Pschvrembel, KJIHHHH6CKHH CJIOBapb). Ķjisi JieMeHHH rnnepjiHnonpoTeHHeMHH no nacToamero epeMeHH πρΗΜβΗίΐιοτ npneMymecTBeHHO cjio%Hbie 3THJiOBbie 3φπρΜ α-(ρ-Χϋ0ρφθΗ0ΚϋΗ)-Η30Μ3€ΛΛΗ0Η KHCJlOTbl, COJIH α - (ρ-ΧΛΟρφθΗΟΚΟΗ)-H30MaCJIBH0H KHCJlOTbl H HHKOTHHOBJTO KHCJIOTy, a TaiOKe npOH3BOAHbie HHKOTHHOBOH KHCJlOTbl, HCKyCTBeHHbie aHH0H0-06MēHHbie CMOJIbI H MHoroHHCjieHHbie KOMOHHHpoeaHbie npenapaTbi. IICKyCTBeHHbie ΕΗΗ0Η0-06μΘΗΗΜΘ CMOJIbI no ηρΗΗΗΗβ CBOHX XHMHHeCKHX Η φΗ3ΗΗ0ΟΚΗΧ CBOHCTB MECTO ΠρΗΒΟΛΗ Κ 3ΗΕ4ΗΤ eJIbHbIM %ejiynoHHo-KHiueHHbiM HenyraM. Ha ochob3hhh cbohx εηηοηο-οομθηημχ CBOHCTB OHH ΜΟΓ)Τ OKa3blBaTb OTpHUaTejIbHOe BJIHHHHe Ha paCCaCbIBaHHe ηρντΗΧ jieKapcTBeHHbix cpencTB h πρπροηΗΜχ MHHepajioB. 3 LV 10839
JleKapcTBēHHbie cpejurrea na pacTHTejibHOH ocHoee, KOTopue mojkho npHMeHHTb AJia jieneHua BbiiueHa3BaHHbix HapyiucHHH o6MeHa BemecTB, ao CHX nop H6H3B0CTHM. Tenepb HeOJKHAaHHO 6bIJIO Η3ΗΛβΗ0, hto rajiaiaypoHOBaa KHCJiOTa noKa3biBaeT ninoxojiecTepHHeMHHecKoe aeficTBHe. ΠρΗ Π0Μ0111Η OnHCaHHbIX HH3K6 ΟΠΜΤΟΒ 6blJ10 ŪOKa3aHO, HTO ΙφΗΘΜ raJiaiCiypOHOBOH KHCJIOTbl HJIH H3BeCTHbIX np0H3B0AHbIX 3T0H KHCJIOTbl npHBOAHT K 3aMCTHOMy CHiDKCHHK) CbIBOpOTOHHOrO XOJieCTepHHa, HTO, cjieaoBaTejibHO, 3to coejuiHeHHe hjih KJiacc coeaHHeHHH oneHb χοροιιιο πρΗΓΟ^ΗΗ fljia jieneHiui nmepjiHnnaeMHH. TaKHM o6pa30M, η3ο6ρθτθηηθ HanpaBJieHO npejKae ecero Ha npHMCHeHHC rajiaKrypOHOBOH khcjīotm, ocoSeHHO a-D-rajiaKTypoHOBOH khcjīotm oGmeft (ļ)opMyjibi COO-R,
« ΠρΗΗβΜ Ri = H, R2 = H H R3 = H, Λιλ nojiyHeHH« JieKapcTBeHHoro cpeacTBa ķsisi προφπ^ΒκτΗΚΗ η λθηθηηβ ΓΗΠερϋΗΠΗΛβΜΗΗ. Zīajiee, H3o6peTeHHe othochtch k πρΗΜβΗβΗΗΚ) nojiHMepoe ra.iaKTypoHOBOH khcjīotm, οοο6θηηο a-D-rajiaKTypoHOBOH khcjīotm o6meii
ή OR; COO-R'ļ o
R'i = H R'2= H R3= H φορΜ^ΠΜ
npHHēM Rj = H r2 = h r3 = h 4 npeacTaBjiAer uejioe hhcjio κλά yKa3aHHOH b nyHKTel uejiH. H3o6peTeHHe BKJiioiaeT TaioKe npHM chch hc cjiojkhoio MemnoBoro 3φκρΒ rajiaKTypoHOBOH khcjiotbi h ee nojiHMepoB, ocoSeHHo a-D-rajiainypoHOBOH khcjiotm ajīh yKā3aHH0H β π>Ήκτε 1 uejiH η aku προφιυΐΒΚΊΉΚΗ η ΛβΊβΗΗΗ aTepociuiepo3a, npmeM Rj = CH3 R’j = CH3 hjih H,
r2 = h r2 = H
R3 = H R 3 = H B paMKax Η3θβρβτβΗΗΛ 3aKJiKmeTCfl TaioKe npuMeHeHHe ajih yica3aHH0H b nyHKTe 3 uejiH coaepxauuix τρβτΗΗΗΜβ hjih HeTBepTHHHbie aMHH-aHH0HOO6MeHHHKH CJIOJKHbK 3φκρ0Β, IipOCTbDi 3φκρ0Β η/HJIH aueTajiefi rajiainypoHOBOH khcjiotm, ocoGemio a-D-rajiaicrypoHOBOH KHCJIOTbl Η HX nOJIHMepOB, ΠρΗΜΘΜ B CJiyHae CJlOJKHOrO 3φκρΒ R2 = - 0 \ R3 = -0 aMHH-aHHOHOBbiH oGmchhhk b oGmeft φορΜ>Μΐβ o6pa3OBaH Mepe3 Rļ = -CH2-R4 r2 = h
R3= H b cjiyqae npocToro 3φπρΒ R'i = H HJIH CH3 R2 hjih R3 = -CH2 - R4 b cjiyqae aaeTajieii R’i = Ri hjih H R2 = H R3 = H, R1 = Rx R 2 = R2 hjih H R’3 = R3 HJIH H, CH - R4 1 5 LV 10839
R6 R4 = CH2 - N — R5 , ^ R6 h npmeM b cjiyMae TpenraHoro βμηηβ r5 = h Η B CJiynae ΗεΤΒβρΤΗΗΗΟΓΟ aMHHa R5 =CH3 hjih R5 =[CH2]m -CH3 hjih Rs = [CH2]m -CH (OH) -CH3 R6 =[CH2]m -CHg , πρΗΜβΜ m npeacTaBJiHeT uejioe hhcjio ot 1 λο 5.
OcOOēHHO npejVIOHTHTeJIbHbIM BapuaHTOM 0CyQieCTBJI6HHH H3o5peTeHHH HBjiaeTCfl πρημθηθηηθ noABeprajroro (ļjepivieHTauHH neKTHHa Λλλ yKa3aHHOH b πγκκτε 1 h 3 uejin. ΠεκτΗΗ mojkho Taione (ļ)epiweHTauHēH npeo6pa30BbieaTb cpaBHHTejibno npocro, b ochobhom, λο α-D- nuiaKTypoHOBOH κμολοτμ.
HaKOHeu, H3o6peTēHHe othochtch Tairae eme κ opajībHO
Ha3Ha4ačM0My jieKapcTBeHHOMy cpeacTBy λλη jieneHHa πιπβρΛΗΠΗΛβΜΗΗ h/hjih aTepocKJiepo3a. Oho OTJiHMaercfl TeM, mto oho εοΛερχΗΤ b KanecTBe aKTHBHoro BemecTBa no MeHbiueH Mepe coejuiHeHHe onncaHHoro b πυηκτθ 1 h 2 hjih 3-5 cocTaea. B npOTHBOnOJIOHCHOCTb HHCTO CHHTēTHHēCKHM ΜεΑΗΚΒΜβΗΤΒΜ BbHIie-Ha3BaHHbie Bemecrea npHHajuieacaT κ πρκροΑΗΜΜ κοΜΠΟΗβΗτβΜ πηιηη. ΠοΛΗΜερΜ rajiaKTypoHOBOH khcjiotu ηβχοακτηι b 6jih3koh cbh3h c neKTHHaMH, KOTopue BcrpenaiOTca ποίτη bo ecex pacTHTenbHbix Κ0ΜΠ0ΗΘΗΤ3Χ. CoejIHHCHHH MOiyT Ha3HaHāTCfl opajībHO ΚΛΚ rpa^HTbl, cupon HJIH CyCneH3HH. JĻjIfl ΛΘΜΘΗΗΛ Η ΠρβΛΟΤΒρΛΙΙΙΘΗΗίΙ 6θΛΘ3ΗβΗΗΗΧ ΤΘ46ΗΗΗ 6ΗΟΜθρφθ3Μ ocoOeHHO ληπιιληογο OajiaHca, κλκ HapyuieHHH oOMeHa eemecTB η 6 Η3Μ6Η£ΗΗίί Β COCyaaX ΠρΗ aTep0CKJiep03e, Η3ΜβΗεΗΗΗ COCyHOB npH flHa6ere, HāpyiI16HHH KpOBOH3JIHHHHH B CeTMHTKy, ΗΒ3ΗΒΗΒΚ)Τ, Β CpeAHCM, βΙΚΘ^ΗβΒΗΟ okojio 10-50 r aKTHBHoro eemecTBa no H3o6peTeHHio. JleKapcTBa Ha3HaqaioT nepezi ochobhmm πρηθμομ πηιηη. B H3Ji02KeHHbix Hn>Ke onbiTax 6biJio aoKa3aHo, hto a-D-rajiaKTypoHOBaa KHCJiOTa, MOHOMep neKTHHa, noKa3biBaeT ranoxojiecTepHHeMHMecKoe ^encTene b cbieopoTKe κροβη. ΓajiaKTypoHOBaa KHCJiOTa b npoTHBonojiožKHOCTb neKTHHy χοροιηο pacTBopHMa b Boae h MOKOT n03T0My, KaK ynOMHHyTO, Hē BbI3bIBaTb ΗΗΚΒΚΗΧ Προβ.ΙΘΜ npH πρπθΜβ. JleneHHe xojiecTepHH6MHH πρκ noMoutH a-D-rajiaKTypoHOBOH KHCJIOTbl ΠΟΗΤΗ Ηβ BbI3biaeT npOŪJieM. TOKCHHeCKHe ΒφφβΚΤΜ H6H3B6CTHM, a-D-rajiaKTypoHOBaa KHCJiOTa npe^CTaBJiaeT caxap, κοτορωπ oneHb nacro BCTpeHaeTca bo μηογηχ pacT£HHHX. B pe3yjibTaTe aueTajibo6pa3Horo CBH3biBaHHa ZIEAE-aHHOHo-ooivieHHOH rpynnbi c /ibvmh H3 τρεχ C-0-rpynn πθκτηηοβογο MOHOMepa rajiaKTypoHOBOH kmcjiotn CHHHcaiomee xojiecrepHH jieftCTBHe b Mo^ejiH xoMaxa mokot npH6jiH3HTejibH0 vūBaHBaTbca.
CjienoBajio 6bi ynoMflHyTb TaioKe, hto bmccto a-D-rajiaKTypoHOBoii KHCJioTbi mokcho 6bijio 6bi npHMeHHTb Taioke [3-D-rajiaKTypoHOByio KHCJiOTy no H3o6peTeHHio. 0;maKO nocjie^HHH 3HaHHT£jibHO aopOKte, TaK hto, KaK npaBHJlO, ΠΟ Η3θ6ρβΤβΗΗΗ) npHMOHHIOT a-D-raJiaKTypOHOByiO KHCJIOTy.
M3Jio>KeHHbie hhjkc οπμτμ hcho zxoKa3biBaK)T, hto npneM
raJiaKTypOHOBOH KHCJIOTbl npHBOilHT K 3HaHHTeJIbHOMy CHHKCCHHIO KOHneHTpauHH xojiecTepHHa h jiHrmuoB, KOTopbie no MCHbincH wepe nacTHHHo HecyT oTBeTCTBeHHOCTb 3a B03HHKHoeeHHe rHnepjiHnHaeMHH h/hjih aTepocmiepo3a. npHBē^eHHbie Ηΐϋκε pe3yjibTaTbi οπμτοβ noKa3biBaiOT, hto ece HccjieaoBaHHbie 3/iecb eemecTBa, κοτορωβ co^epncaT a-D-rajiaKTypoHOByio KHCJIOTy, HBJIHIOTH 3φφβΚΤΗΒΗΜΜΗ. MēTHJIHpOBaHHe KHCJIOTHOH ΓρΥΠΠΜ rajiaKTypoHOBOH KHCJIOTbl jiHiiib He3HaHHT6JibHO bjihhct Ha aeifCTBHe a-D-rajiaKTypoHOBOH khcjioth, a-D-rajiaKTypoHOBaa KHCJiOTa KaK b KanecTBe 7 7LV 10839 MOHOMepa, TaK h b KanecTBe nojiHMepa HMeeT npH6jiH3HTejibHO οληηβκοβυιο 3φφεΚΊΉΒΗΟ(ΤΠ>. B pe3yjibTaTe φερΜεΗΤΒΚΗΗ πεκτΗΗΒ TaiOKe o6pa3y8TCH, b ochobhom, rajiaKTypoHOBaa KHCJioTa, TaK ito mojkho, cjieaoBaTejibHO, npHMBHBTb φερΜεΗΤΗρΟΒΒΗΗΗΗ ΠεΚΤΗΗ.
OaHaKo 3aMBm8HHe 3ηηοηο-ο6μθηηοη rpynnbi ame pa3 οπρεΛβΛεΗΗο noBbimaeT 3φφεκτΗΒΗ0?π>. 3το noBhiuieHHe o6ycjioBJi8Ho amioHO-oOivreHHOH eMKOCTbio τρετκΗΗΟΓΟ a30Ta Γ1ΕΑΕ-6οκοβοη rpynnu. IIoBbiiueHHB 3φφεκτΗΒΗοετΗ HaBBpHBKa AOCTHraiOT Tairace apyniMH, coAepacauuiMH ΤρεΤΗΗΗΜε HJ1H ΜβΤΒερΤΗΗΗΜε aMHHbl aHHOHO-o6M8HHbIMH ipjTinaMH. Πο 3THM npHMHHaM OHBBHAHO, HTO BCB 3aHBJI8HHbie BeHļBCTBa K&K H ΓΗΠΟΛΗΠΗΛεΜΗΗεεΚΗε H aHTHaTBpOCKJI8pOTHH8CKH8 JIBKapCTBCHHblB CpBACTBa BBJUHOTCH 3φφεΚΤΗΒΗΜΜΗ.
OaPMaKOJionraecKoe McnbrraHue rajiaKTypoHOBaa KHCJioTa h ee npoH3BOAHbie, KaK npaBHJio, χοροιπο περεΗοεΗΜΜ. JIAso nojiHMepoB rajiaKTypoHOBOH khcjiotm cocraBJuieT 3HaHHT8JIbHO BblDie 10 γ/ΚΤ y Kpbic, ΧΟΜΒΚΟΒ H KpOJIHKOB. H APJTHB BbIUIBHa3BaHHbIB C08AHH8HH5I HM8I0T Π0Λ06η)ΠΚ> XpOUiyiO COBMBCTHMOCTb. Bjiaronapa hx poacrBy hjih npHHajouiexHOCTH κ πρκροΛΗΜΜ κομποηβητημ ΠΗφΗ rapaHTHpoeaHa 68306HJIH0CTb COBflHHBHHH.
IlpejKJiHHHMecKoe Hcnbrramie
OnbīT 1: ĪIo 20 30JioTHCTbix χομλκοβ mjokckoio nojia B 3 rpynnax KOPMHJIH 4 HBAejlH ΛΜΠΗΤεΜΗΜεεΚΟΗ ΑΗεΤΟΗ (/Uf8Ta πρκ COABpxaHHH ΧΟΜΛΚΟΒ Η 2% xoji8CT8pHHa). ΚορΜ AByx rpynn, κοτορΜε JiemuiH, oOoramajiH A0n0JIHHT8JIbH0 ΠΟ 5% raJiaKTJļJOHOBOH KHCJIOTbl HJIH jļļEAE-nOJIHrajiaKTypOHOBOH KHCJIOTbl (jJEAE = HH3THJiaMHH03THJl). 8 npHHHMaeMafl ,303a cocraejinjia Me«ay 4 h 5 γ/κγ Beca Tejia h 3a cjtkh.
Mepe3 4 He^ejin >KHBOTHbix yMepTB.ia.in h H3Mepa.iH KOHueHTpaiiHH) jiHnma b CbiBopoTKe κροΒΗ h b πβπβΗΗ. Pe3yjibTaTbi aHajiH30B o6o6meHbi B Ta6jiHue 1,2 h 3. rajiaKrypoHOBaa KHCJioTa nocjie qeTbipexHeAejibHoro jieneHHa CHHJKaeT 3HaHHTejibHO b CbiBopoTKe κροΒΗ KOHiteHTpaiuiiO o6mero xojiecTepuHa na 20%, HDL - xojiecTepuHa na 20%, LDL-x<wiecTepHHa Ha 23%, VLDL- h LDL>xojiecTepHHa Ha 20% h cbo6oahoio xojiecTepuHa Ha 19% (P < 0,05). KpoMe τογο, rajiaKTypoHOBaa KHCJioTa 3HaiHTejibHo CHH%ajia b cbiBopoTKe κροβη o6myio KOHueHTpauHio JiHmma Ha 18% h KOHueHTpaitHH) φοεφο^ΗΠΗ^Β Ha 17%. Aajiee, 6biJia eme 3Ha4HTejibH0 noHHJKeHa o6maa KOHueHTpaima Jinnima b neqeHH Ha 34%. /IEAE-nojiHrajiaKTypoHOBaa KHCJioTa nocjie HeTbipexHe.qejibHoro jieneHHa 3Ha4HTejibHO CHiratajia b ΟΜΒοροτκε κροβη KOHueHTpaunio ecero xojiecTepnHa Ha 43%, HDL-xojiecTepHHa na 47%, LDL-xo;iecTepHHa na 46%, VLDL - xojiecTepHHa Ha 24% h VLDL-njnoc LDL - xojiecTepHHa Ha 41% no cpaBHeHHio c KOHTpojibHbiMH %HBOTHbiMH. KpoMe τογο, 6buia eme 3Hā4HTejibH0 CHHJKeHa o6maa KOHueHTpauna αηπηαοβ Ha 37% n KOHUeHTpauna φΟϋφΟΛΗΠΗΛΟΒ Ha 41% ΠΟ CpaBHeHHIO C KOHTpOJIbHbIMH HCHBOTHbIMH.
KoHneHTpanna xojiecTep«Ha b neaeHH Sbi.ia 3Ha4HTejibH0 CHmKeHa y iKMBOTHbK, κοτορβιχ jieHHJiH npH noMomn i!ELVE-nojiHrajiaKTypoHOBOH KHCJioTbi, Ha 21% n o6maa KOHiieHTpamifl JiHnitaoB β neqeHH Ha 44% b npOTHBOnOJlOHCHOCTb KOHTpOJIbHbIM JKHBOTHbIM. 9 9LV 10839 Οπμτ 2: Πο 20 30JI0THCTbIX ΧΟΜΗΚΟΒ MpKCKOIO nOJia Β 3 rpynnax JieMHJlH 4 He/ļejiH KāK oimcaHHbix b nyHKTe 1 κηβοτημχ. Tpynny 2 Jiemum npn noMoiUH 5%-hoh no.iHrajiaKrypoHOBOH khcjiotm, rpynny 3 JieMHJlH npn ĪIOMOIUH 5%-HOrO CJlOJKHOrO ΜβΤΗΛΟΒΟΓΟ 3φπρ3 nOJlHrajiaKTJļJOHOBOH KHCJioTM b KopMe. rpvnna 1 6buia KompojieM jihīihacmhh. KoHueHTpaium jirniima b cuBopoTKe κροΒΗ η β πθηθηη nocjie HeTbipexHeziejibHoro jieiemiB o6o6metibi b TaOjiHue 4,5,6.
IlojiHrajiaKTypoHOBaH KHCJioTa CHiratajia 3Ha<iHTejibH0 b CbieopoTKe κροΒΗ nocjie HeTbipēxHeAejibHoro Jie»ieHHfl b npoTHBonojiojKHocTb KOHTpOJIbHbIM HCHBOTHbIM ΟβίΗΗΗ ΧΟΛβΟΤβρΗΗ Ha 13%, HDL - xojiecTepHH na 15% h CBo6oAHbiH xojiecrepHH Ha 32%, a Tairae o6myio KOHueHTpamno JIHnimOB Ha 14% H KOHUeHTpaiIHK) φοεφΟΛΗΠΗΛΟΒ na 19% (P < 0,05 Ta6jiHua 4 η 5). Aajiee, JieneHHe nojiHrajiaKTypoHOBOH khcjiotoh 3HaHHTejibH0 CHHHtajio KOHueHTpauHio xojiecrepHHa β πθηθηη Ha 26% h KOHueHTpaumo ecero Jirnmua b nesenu Ha 25%.
CjIOJKHblH ΜΘΤΗΛΟΒΜΗ 3φπρ nOJIHraJiaKTJļJOHOBOH KHCJIOTbl nocjie HeTbipexHe^ejibHoro iieHeHHH 3HaHHTejibHO CHH*aji b CbieopoTKe κροβη KOHueHTpauHio o6mero xojiecTepHHa (-24%), HDL-(-24%), LDL-(-23%), VLDL-(-44%), VLDL- iuiioc LDL-(-22%) h cboOoahoio xojiecTepnHa (J\°41%) (Ta6jiHua 4). .Hajiee, cjioacHbiH MemnoBbiH 3φπρ nojiHrajiaKTypoHOBOH khcjiotm 3HaHHTeJIbHO CHHHiaJI B CbieopoTKe ΚΡΟΒΗ KOHIteHTpaimiO οδΐΗΗΧ ΛΗΠΗϋΟΒ Ha
18% η φοεφοΛΗΠΗαοΒ Ha 23% (Ta6jiHua 5). B neneHH cjiojkhmh MemioBbiH 3φπρ IIOJIHrajiaKTypOHOBOH KHCJIOTM 3HaiHTejIbHO CHIDKa.1 KOHUeHTpaUHIO xojiecTepHHa Ha 29% h KOHueHTpaiiHio Bcex ληπηο,οβ Ha 32%. IIojivgeHHe Φθρμ6ητητήβηοιό πθκτηηβ: ΠρΗΜθΗΗΐοτ 50 mmoji N-> aH2P04 - δ^τφβρκοΓΟ pacTBopa c pH 4,5, 60°C η 1 r neKTHHa3bi/ji (neKTHHa3a 5S, Serva Aspergillus niger, 0,66 10 eAHHHlt/Mr). B 3T0T paCTBOp 3aMeiUHBaiOT B TeneHHe HeCKOJlbKHX MaCOB nOCTeneHHO ΠβΚΤΗΗ Η ΛΟ ΚΟΗβΊΗΟΗ KOHUeHTpaiļHH OKOJIO 500 r/jl H Ha 1 ΚΓ neKTHHa Ao6aBJiHH)T lOr neKTHHa3bi. BejnrmHa pH ycTaHaB.THBaeTCH AoOaBKOH 5-MojmpHOH NaOH b 4,5.
TaOjiuua 1 KOHUeHTpaima XOJieCTepHHa B CblBOpOTKe ΚρΟΒΗ Χ0ΜΛΚ3 nocjie HeTbipexHeaejibHoro JieneHivi (n=20 /rpynna)
CpeAHHe BejieHHHbi [μγ/hji] ± CTaimapTHoe οτιυιοΗβΗΗβ (SD) KOHTpOJIb ra.iaKiypoHOBaa KHCJiOTa flEAE- nojnirajiaKTypouoBa Λ KHCJiOTa 06iuhh xo.iecTepHH 340 271* 193* SD ±53 ±31 ±40 D -20 -43 HDL-xo.iecTepHH 148 118* 79* SD ±23 ±21 ±13 D -20 -47 LDL-xo.iecTepHH 151 117* 82* SD ±42 ±24 ±24 D -23 -46 VLDL-xo.iecTepHH 42 36 32* SD ±10 ±12 ±8 D -14 -24 VLDL-+LDL-xojiecTepHH 192 153* 114* SD ±47 ±22 ±30 D -20 -41 CBo6oaHMH xojiecTepHH 118 96* 103 SD ±28 ±19 ±20 D -19 -13 D = pa3H0CTb b % b nepecneTe Ha KOHTpoJibHyio rpynny * 3HaHHMOCTb p < 0,05. 11 LV 10839
TaOjiHua 2 KOHIieHTpaiUUI JIHIIiiaOB B CbIBOpOTKe κροβΗ χομβκβ nocjie MeTbipēxHeziejibHoro jieneHHfl (n=20/rpynna)
CpeAHHe BejimHHbi [μγ/ολ]± CTanaapTHoe οτΐϋΐΟΗβΗΗβ (SD) KOHTpOJIb rajiaKTypoHOBan ΛΕΑΕ- KHCJioTa nojiHrajiaKTypoHOBaa KHCJioTa OOiime -ιηπηαμ 1295 1060* 819* SD ±177 ±153 ±135 D -18 -37 φΟΟφο.ΊΗΠΗΑΜ 389 322* 228* SD ±48 ±40 ±31 D -17 -41 TpHrjIHIiepHAbl 202 216 188 SD ±76 ±82 ±55 D +7 -7 TaOjiHiia 3 KOHUeHipaUHB JinnUaOB B ne^eHH (μγ/γ MOKpbiH Bec) ΧΟΜΒΚΟΒ nocjie qeTbipexHeAejibHoro jieneHHH (n =20/rpynna) Cpeoiuie BejiHHHHbi [μγ/γ MOKpbiH Bec]± craimapTHoe otkjiohchhc (SD) KOHTpOJIb rajiaKTypoHOBasi ΛΕΑΕ- KHCJioTa nojiHrajiaKTypoHOBaa KHCJioTa XojiecTepHH 30 27 24* SD ±3 ±6 ±8 D -9 -21 06mne JIHIIHAbl 169 111* 94* SD ±22 ±25 ±33 D -34 -44 D=pa3H0CTb b % b nepecnere na KOHTpojibHyio rpynny * 3HaHHMOCTb p < 0,05 12
TaOjiima 4
KoHueHTpaiiHfl xojiecTepHHa b cueopoTKe κροβΗ xoM»Ka nocjie HeTbipexHeaejibHoro JieHēHHa (n=20/rpynna)
CpeAHue BejiHHHHbi [μγ/aji] ± craitaapTHoe OTKjiOHemie (SD) KOHTpOJIb CnojKHbiH MenuiOBbiH 3φκρ nojiHraaaKTypoHOBOH KHCJIOTbl IlojiiirajiaKijpoHOBaa KHcaoTa ΟβφΗΗ xojiecTepHH 414 314* 361* SD ±54 ±44 ±49 D -24 -13 HDL-xojiecTepHH 175 133* 149* SD ±26 ±19 ±23 D -24 -15 LDL-xojiecTepHH 199 153* 163 SD ±63 ±36 ±38 D -23 -18 VLDL-xojiecTepHH 50 28* 48 SD ±24 ±12 ±16 D -44 -4 VLDL-+LDL- xojiecTepHH 231 181* 212 SD ±47 ±41 ±42 D -22 -8 CB060JIHblH xojiecTepHH 117 69* 80* SD ±17 ±10 ±13 D -41 -32 D=pa3HOCTb b % b nepecnere Ha KOHTpojibHyio rpynny * 3HaMHM0CTb p < 0,05 13 LV 10839
TaOjiHiia 5 KoHueHTpamm λμπηλοβ b cbieopoTKe κροβπ xoMaita nocjie MeTbipexHe^eJibHoro jieqeHHa (n=20/rpynna) CpeoHHe BejiHHHHbi [μγ/λλ] ± CTamapTHoe οπαιΟΗβΗΗβ (SD) KOHipOJIb CjlOJKHblH MeTHJIOBblH 3φΗρ nojiHrajiaiojpoHO BOH KHCJĪOTbl IIojiHrajiaKTypoH OBafl KHCjioTa 06lUHe JlHnHUbl 1563 1286* 1338* SD ±151 ±181 ±201 D -18 -14 φοοφο.ΙΗΠΗΛΒΙ 474 365* 385* SD ±52 ±44 ±47 D -23 -19 TpHrJIHUepHHbī 270 265 269 SD ±59 ±80 ±89 D -2 14
Ta6jinua 6 KOHUeHTpaUHH ΛΗΠΗΛΟΒ B ΠεΜβΗΗ (μγ/γ MOKpblīi) y ΧΟΜΗΚΟΒ nocjie HeTbipexHeaejibHoro λθμθηηλ (n=20/rpynna) Cpe/ume eejiHMHHbi [μγ/γ] MOKpbiif Bec ± CTamapTHoe oTKJiOHeHHe (SD) KOHTpOJIb CilOJKHblH MeTHJlOBblft 3φΗρ nOJlHrajIāKTypOHOBOH KHCJlOTbl IIoJiHrajiaKTypoHOBaH KHCJioTa XojiecTep»H 30,0 21,3* 22,1* SD ±3,8 ±7,3 ±4,9 D -29 -26 06mwe jimihum 89,4 60,4* 67,4* SD ±11,6 ±17,4 ±23,0 D -32 -25 D = pa3H0CTb b % b nepecMeTe Ha KOHTpojibHyio rpynny * 3Ha»IHMOCTb p < 0,05 15 LV 10839
ΦΟΡΜΥΛΑ H30BPETEHHH 1. JleKapcTBeHHoe cpeacTBO jum προφιυΐΒκτΗΚΗ h jieneHHJi HapyuieHHH jinnouzmoro h xojiecTepHHOBoro o6Mena eemecTB, OTJiHHaiomeeca τβΜ, mto b KaiecTBe βκτηβηογο KOMnoHeHTa oho conepaoiT rajiaKTypoHOByio KHCJioTy hjih ee npou3BOAHoe η, πρη ηθο6χολημοοτη, ueji€%ie Ao6aBK«. 2. JleKapcTBeHHoe cpe^cTBO no n.l, OTjnmiomeecH τβΜ, mto b KanecTBe rajiaKTypoHOBOH khcjiotm, oho conepJKHT a-D-rajiaKTypoHOByio KHCJioTy οδιηβΐι φορΜ^Μ CGO-R,
ΠρΗΗβΜ Rļ=H, R2=Hh R3=H, 3. JleKapcTBeHHoe cpe^cTBO no n.l, oTJiHHaiomeecji τβΜ, hto b nanecTBe προη3βοαηογο rajiaKTypoHOBOH khcjiotm oho coaepjKHT nojiHMep a-rajiaKTypoHOBOH khcjiotm o6uien φορΜ^Μ.
Rj = H r2 = h ΠρΗΗβΜ Rj=H R2=H h 16 R3=H R3 = Η η n o6o3HaHaeT nejioe hhcjio, λιιη yKa3aHHoii b nyHKTe 1 uejiH. 4. JleKapcTeeHHoe cpejicTBO no n.l, OTJiHHaiomeecH τθμ, hto b KanecTBe προη3βοληογο rajiaKTypOHOBOH KHCJioTbi oho cojiepjKHT cjiojkhmh MeTHjiOBbiH 3φηρ rajiaKTypoHOBOH khcjiotm h eē nojiHMepoe npHHevi Rļ=CH3 R i = CH3 hjih H,
R2=H R2 = H
R3=H R3 = H
5. JleKapcTseHHoe cpejicTBO no n.l, OTjiHHaioiueecji τεΜ, hto β KanecTee npoH3BOAHoro rajiaKTypoHOBon khcjiotm oho co^epaorr TpeTHHHbie HJIH HeTBepTHMHbie aMHH-aHH0H006MeHHHKH CJIOJKHbIX 3φηρθΒ, npOCTbIX 3φκροΒ h/hjih aneTajieii rajiaKTypoHOBOH khcjiotm, oco6eHHO a-D-rajiaKTypoHOBoi< KHCjioTbi h eē nojiHMepoe, npuneni b cjiynae cjiojkhoio 3φπρη R’l = Rļ hjih H r2 = h r3 = h R'i =Ri R 2=R2 hjih H R’3=R3 hjih H,
Ri= - CH2 - R4 r2=h r3=h b cjiynae npocToro 3φκρα Ri=H hjih CH3 R2 hjih R3 = -CH2 -R4 b cjiynae aueTajien
R2= O r3= o 6. JleitapcTBeHHoe cpeacTBo no n.l, OTJiimaiomeecH τθμ, hto b KanecTBe προη3βοαηογο rajiaKTypoHOBOH khcjiotm oho co/iepaurr φερΜβΗΤΗρΟΒΒΗΗΜΗ ΠβΚΤΗΗ. LV 10839 17 7. Cnoco6 jieneHHH η npo(ļ)HJiaKTHKH HapyuieHHH JimiOHHHoro h xojiecTepHHOBoro o6MeHa eeiuecTB, OTJiHHaioiUHHCfl τβΜ, hto Hcnojib3yioT cpe^CTBO no n.1-5. 18 LV 10839
Pe(J)epaT ΠρβΛΛΟ*βΗΟ Cpe^CTBO Α1Λ npO(ļ)HJiaKTHKH Η ΛΘΜΘΗΗΗ HapjTIieHHH jinnoKOHoro η xojiecTepHHOBoro o6MēHa BemecTB, co^ep)Kamee b Ka^ecrae ΒΚΤΗΒΗΟΓΟ Κ0ΜΠ0Η6ΗΤΒ rajiaKTJļlOHOBJTO KHCJ10Ty HJIH eē ΠρθΗ3ΒΟΛΗΟβ. ΠρβΛΛ0*βΗ Taicxe cnoco6 JieneHHa η προφΗΛβκτΗΚΗ HapyuieHHH ΛΗΠΟΗΛΗΟΓΟ H XOJlēCTepHHOBOrO ofiMCHa BemeCTB C HCn0Jlb30BaHHeM 3ΤΟΓΟ cpeacTea.
Claims (2)
- LV 10839 IZGUDROJUMA FORMULA 1. Ārstniecības līdzekli b lipīclu un hole sterīna vielumaiņas traucējumu profilakeei un ārstēšanai, kas atšķiras ar to, ka taB kā aktīvo vielu satur galakturon-Bkābi vai tās atvasinājumu un, nepieciešamības gadījumā, atbilstošas piedevas. 2. Ārstniecības līdzekli s pēo punkta 1, kas atšķiras ar to, ka tā sastāvā ietilpsošā galakturonskābe ir α-D-galakturonskābe ar formulu (I) C00R41 3. Ārstniecības līdzeklis pēc punkta 1, šajā punktā norādītajiem mērķiem, kas atšķiras ar to, ka tā sastāvā ietilpstošais galakturonskābes atvasinājums ir a-galaktu-ronskābes polimērs ar formulu (II)4. Ārstniecības līdzeklis pēc punkta 1, kas atšķiras ar to, ka tā sastāvā ietilpstošais galakturonskābes atvasinājums ir galakturonskābes (I) vai tās polimēru (II) mr.4· ' 1 η r\ η UXXCO liCi'ID eii ‘ MVIU (T \ TT^ 4 i TT \ i*,i** n * Klu· t\ Anu n ,, v% XUA‘UiUXU \l; v tu 's-LJ- ) J Xi‘ Ull-3 p ) x\ Ull Λ t Λ Ό ’ ntl 1-rr*. A tT 0 » -5 t . nt- ,, T) 4 »» TI i\ ιι· uii-3 vdi ii V Λ UU r\ ιι ii • Αγ* ti i.r 11 f 5. Ārstniecības līdzeklis pēc punkta 1, kas atšķiras ar to, ka tā sastāvā ietilpstošais galakturon- skābes atvasinājums ir trešējais vai ceturtējais amīns - anjonīts uz galakturonskābes esteru, ēteru un / vai aoetālu bāzes, sevišķi, uz ^-D-galakturoskābes un tās polimēru bāzes, pie kam: estera gadījumā formulās (I) un (II): n1 ,·„ ntj t)4 r)2 n3 ·„ τι -0^4.-. T)1 ti r)2,,,v, n3'.*n τι. K χι· *"υΠη“Κ p K Luī rt xi* lip r\ 1P r\ vsu It * i\ un r\ χΡ Π, cl — etera gadījumā formulas (I) un (II): R ir K vai CH-,, R" un R ir A 1' 1 θ' p . P« τ πττ n^· π · 4« η ι n<- ί»» η£· ..η4ττ η^ n-r ττ5ί τι. “uu^n , η χι· γ\ , η ιι· χ\ veu.ii, r\ υ· r\ ναι ιι, 2 LV 10839 aoetālu gadījumā formulās (I) un (II): O 7 Γ1 1 Tī'*' Λ Λ 1 Τ'! 1 r\ cili r\ iN.«u»jj<a vciuu ģruyu -o, \ c2- R = -0 p;6 Γ\ \ λ* rs #-% m " v\ rt _ η *4·« t»Q* ^.4 ņ n «mn n vsi ^ Γ)^ · _ΠΙΙ IT tvam <am.Li.io οιι^Αίχυο vox<av->wo «aP £i-u.±/U x\ · % R6 un trešajā smīna gadījuma R^ ir K; un oeturtejā smīna gadījuma n5 nu Tr-,i (nu ^ _nu ..~i (nu \ nu(r\w\ rv χχ- —uii-3 Veli — \uxxn Vtaj. - vv-αχ^wxx ^xx i—ΠΚ · ^ c »u ·*? c. iii ' 3 ’ » . m τ « (nu Λ nu »ii Λ X r-. *n m * n *r»-,nrtl rt ļ J* T — T r Liii χ\ χι· — '-'ΧΧ'ϊ j ν-*-^ ^>ii ui χχ· vcocxo oxv«axtxxB ηθ 1 lldS 0. C. Īli j 6. Ā p ē t n i e o i b a e līdzeklis pēo punkta 1, kas atšķiras ar to, ka tā sastāvā ietilpstošais galakturon-skāhes atvasinājums ir fermentēts pektīns.
- 7. Paņēmiens lipīdu un holesterīnu vielumainas trau cējumu ārstēšanai un profilaksei, kas atšķiras ar to, ka izmanto līdzekli pēo punktiem 1-5. 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4011285A DE4011285A1 (de) | 1990-04-06 | 1990-04-06 | Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose |
| PCT/EP1991/000654 WO1991015214A1 (de) | 1990-04-06 | 1991-04-06 | Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10839A LV10839A (lv) | 1995-10-20 |
| LV10839B true LV10839B (en) | 1996-04-20 |
Family
ID=6403968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-93-1238A LV10839B (en) | 1990-04-06 | 1993-11-17 | Remedy for prophylactics and treatment of lipoid and cholesterol metabolism upset, method for prophylactics and treatment thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5434141A (lv) |
| EP (1) | EP0476113B1 (lv) |
| JP (1) | JPH05500673A (lv) |
| KR (1) | KR920700656A (lv) |
| AT (1) | ATE135223T1 (lv) |
| AU (1) | AU639097B2 (lv) |
| CA (1) | CA2063588A1 (lv) |
| DE (2) | DE4011285A1 (lv) |
| DK (1) | DK0476113T3 (lv) |
| ES (1) | ES2086538T3 (lv) |
| GR (1) | GR3019866T3 (lv) |
| HU (1) | HU218925B (lv) |
| LT (1) | LT3543B (lv) |
| LV (1) | LV10839B (lv) |
| RU (1) | RU2108788C1 (lv) |
| UA (1) | UA35566C2 (lv) |
| WO (1) | WO1991015214A1 (lv) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6084067A (en) * | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
| US6824779B1 (en) | 1993-07-26 | 2004-11-30 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting the interaction of B7-2 with its natural ligand |
| JPH0948732A (ja) * | 1995-08-04 | 1997-02-18 | Pola Chem Ind Inc | 活性酸素消去剤及びそれを含む組成物 |
| US6929807B1 (en) | 1996-08-09 | 2005-08-16 | Mannatech, Inc. | Compositions of plant carbohydrates as dietary supplements |
| ATE218065T1 (de) * | 1996-08-09 | 2002-06-15 | Mannatech Inc | Zusammensetzungen auf pflanzliicher kohlenhydratbasis als nahrungsergänzungsstoffe |
| US5942500A (en) * | 1998-04-27 | 1999-08-24 | Perry; Stephen C. | Dietary composition to reduce dietary fats |
| US6462029B1 (en) * | 1999-02-23 | 2002-10-08 | Econugenics | Compositions and methods for treating mammals with modified alginates and modified pectins |
| WO2008011216A2 (en) | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| WO2012138213A1 (en) * | 2011-04-08 | 2012-10-11 | N.V. Nutricia | Reduction of vascular dysfunction with specific saccharides |
| EP2755480B1 (en) * | 2011-09-16 | 2021-03-31 | Galectin Therapeutics Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| BR112014030534A2 (pt) | 2012-06-06 | 2017-06-27 | Galectin Therapeutics Inc | composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2370961A (en) * | 1941-11-15 | 1945-03-06 | Rohm & Haas | Preparation of alpha-d-galacturonic acid |
| DE2036605A1 (de) * | 1970-07-23 | 1972-05-31 | Mylaeus, Armin, 5970 Plettenberg | Diätbrot und Verfahren zu seiner Herstellung |
| DE2521765B2 (de) * | 1975-05-16 | 1979-01-18 | Valentin Dr.Med. Koehler | Verwendung von D-Glucuronsäure, dessen γ -Lacton, Galacturonsäure oder Mannuronsäure |
| US4122179A (en) * | 1976-06-03 | 1978-10-24 | Enrico Corvi Mora | Acid addition salts of vincamine and apovincamine |
| JPS54119038A (en) * | 1978-03-07 | 1979-09-14 | Takeda Chemical Industries Ltd | Digestion difficult polysaccaride containing food |
| FR2449452A1 (fr) * | 1978-11-15 | 1980-09-19 | Krauter Henri | Nouveau medicament utile notamment comme diuretique et detoxicant, derive de l'acide galacturonique |
| JPS59206045A (ja) * | 1983-05-11 | 1984-11-21 | Asahi Chem Ind Co Ltd | 低比重リポ蛋白質吸着材 |
| DD271415A3 (de) * | 1983-07-05 | 1989-09-06 | Akad Wissenschaften Ddr | Verfahren zur herstellung eines pektindiaetetikums |
| US4617276A (en) * | 1985-01-23 | 1986-10-14 | Agway Inc. | Novel method for quantitating structural and non-structural carbohydrates in feedstuffs |
| US4615891A (en) * | 1985-01-23 | 1986-10-07 | Agway Inc. | Method of formulating dairy cow rations based on carbohydrate regulation |
| US5063210A (en) * | 1989-04-20 | 1991-11-05 | Lange Iii Louis G | Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption |
| DK81690D0 (da) * | 1990-03-30 | 1990-03-30 | Grindsted Prod As | Pektinprodukt og fremgangsmaade til fremstilling deraf |
-
1990
- 1990-04-06 DE DE4011285A patent/DE4011285A1/de not_active Withdrawn
-
1991
- 1991-04-06 WO PCT/EP1991/000654 patent/WO1991015214A1/de active IP Right Grant
- 1991-04-06 RU SU5010708A patent/RU2108788C1/ru active
- 1991-04-06 AT AT91907526T patent/ATE135223T1/de not_active IP Right Cessation
- 1991-04-06 KR KR1019910701794A patent/KR920700656A/ko not_active Application Discontinuation
- 1991-04-06 UA UA93004372A patent/UA35566C2/uk unknown
- 1991-04-06 JP JP3506851A patent/JPH05500673A/ja active Pending
- 1991-04-06 US US07/777,523 patent/US5434141A/en not_active Expired - Fee Related
- 1991-04-06 ES ES91907526T patent/ES2086538T3/es not_active Expired - Lifetime
- 1991-04-06 EP EP91907526A patent/EP0476113B1/de not_active Expired - Lifetime
- 1991-04-06 HU HU814/91A patent/HU218925B/hu not_active IP Right Cessation
- 1991-04-06 DK DK91907526.7T patent/DK0476113T3/da active
- 1991-04-06 DE DE59107536T patent/DE59107536D1/de not_active Expired - Fee Related
- 1991-04-06 AU AU76649/91A patent/AU639097B2/en not_active Ceased
- 1991-04-06 CA CA002063588A patent/CA2063588A1/en not_active Abandoned
-
1993
- 1993-11-17 LV LVP-93-1238A patent/LV10839B/lv unknown
- 1993-12-06 LT LTIP1534A patent/LT3543B/lt not_active IP Right Cessation
-
1996
- 1996-05-08 GR GR960401252T patent/GR3019866T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR3019866T3 (en) | 1996-08-31 |
| UA35566C2 (uk) | 2001-04-16 |
| JPH05500673A (ja) | 1993-02-12 |
| AU639097B2 (en) | 1993-07-15 |
| RU2108788C1 (ru) | 1998-04-20 |
| EP0476113A1 (de) | 1992-03-25 |
| HU218925B (hu) | 2000-12-28 |
| ES2086538T3 (es) | 1996-07-01 |
| ATE135223T1 (de) | 1996-03-15 |
| CA2063588A1 (en) | 1991-10-07 |
| LV10839A (lv) | 1995-10-20 |
| US5434141A (en) | 1995-07-18 |
| DE4011285A1 (de) | 1991-10-10 |
| LTIP1534A (en) | 1995-06-26 |
| HUT61199A (en) | 1992-12-28 |
| DK0476113T3 (da) | 1996-07-15 |
| EP0476113B1 (de) | 1996-03-13 |
| KR920700656A (ko) | 1992-08-10 |
| WO1991015214A1 (de) | 1991-10-17 |
| DE59107536D1 (de) | 1996-04-18 |
| AU7664991A (en) | 1991-10-30 |
| HU913814D0 (en) | 1992-04-28 |
| LT3543B (en) | 1995-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV10839B (en) | Remedy for prophylactics and treatment of lipoid and cholesterol metabolism upset, method for prophylactics and treatment thereof | |
| JP6656345B2 (ja) | 治療指数の改善されたニトロキシル供与体 | |
| US2108765A (en) | Preserving and disinfecting media | |
| CA2614885C (en) | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | |
| EP0996448B1 (en) | Treatment and prevention of adhesions | |
| JP2002502423A (ja) | 進行性組織壊死、再灌流損傷、細菌トランスロケーションおよび成人呼吸窮迫症候群の予防方法 | |
| EP2061530B1 (en) | Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders | |
| JP2011087931A (ja) | 生体吸収性外科手術用組成物 | |
| JP2019513795A5 (lv) | ||
| US5922701A (en) | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue | |
| Davis et al. | Attenuation of aortic aneurysms with stem cells from different genders | |
| Servais et al. | Functional mechanics of a pectin-based pleural sealant after lung injury | |
| US10463610B2 (en) | Composition comprising diacid derivatives and their use in the treatment of collagenic eye disorders | |
| Schreinemacher et al. | Collagen fleeces do not improve colonic anastomotic strength but increase bowel obstructions in an experimental rat model | |
| EP0875246A1 (en) | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer | |
| EP2968698B1 (en) | Coating for drug release | |
| Zahger et al. | VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat | |
| Kamitani et al. | Prevention of retrosternal adhesion by novel biocompatible glue derived from food additives | |
| WO1981000566A1 (en) | N-(hydroxymethyl)-n-(1,3-dihydroxymethyl-2,5-dioxo-4-imidazolidinyl)-n'-(hydroxymethyl)urea,preservative compositions and use thereof | |
| Galanopoulos et al. | The effects of iloprost on colonic anastomotic healing in rats | |
| Higo et al. | Preoperative embolization for paraganglioma | |
| RU94046058A (ru) | Агент для лечения и профилактики катаракты, способ его получения, применение (+) - (2s, 3s)-3 (s)-3-метил-1-(3-метилбутилкарбомоил)бутилкарбамоил]-2-оксикарбоновой кислоты ее соли и ее этилового эфира для получения агента, способ лечения и профилактики катаракты, способ получения водного раствора | |
| AU2012244256B2 (en) | Novel drug delivery devices | |
| CN112316134A (zh) | Pd-1作为静脉移植物术后预防内膜增生的药物的应用 | |
| US20020010210A1 (en) | Pharmaceutical preparation and method for treating cancer |